---
title: "FATE.US (FATE.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/FATE.US/news.md"
symbol: "FATE.US"
name: "FATE.US"
parent: "https://longbridge.com/en/quote/FATE.US.md"
datetime: "2026-05-21T03:16:49.910Z"
locales:
  - [en](https://longbridge.com/en/quote/FATE.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/FATE.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/FATE.US/news.md)
---

# FATE.US (FATE.US) — Related News

### [Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation](https://longbridge.com/en/news/286495998.md)
*2026-05-15T02:14:42.000Z*
> Fate Therapeutics (FATE) reported Q1 losses of $31.2 million and a basic EPS loss of $0.26, raising concerns over its hi

### [Pre-market hot trades in US stocks: Fate Therap pre-market down 7.73%; MACOM Technology Solutions Holdings pre-market up 7.44%](https://longbridge.com/en/news/286416403.md)
*2026-05-14T12:27:56.000Z*
> Fate Therap pre-market down 7.73%; MACOM Technology Solutions Holdings pre-market up 7.44%; Snail pre-market up 182.43%;

### [Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies](https://longbridge.com/en/news/286304011.md)
*2026-05-13T18:45:51.000Z*
> Needham analyst Gil Blum has maintained a Hold rating on FATE stock due to uncertainties surrounding the FT819 program i

### [Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks](https://longbridge.com/en/news/286304395.md)
*2026-05-13T18:45:17.000Z*
> TD Cowen analyst Tara Bancroft has reiterated a Hold rating on FATE stock, citing a balance of promising clinical moment

### [Fate Therap | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.299 M](https://longbridge.com/en/news/286262107.md)
*2026-05-13T12:33:52.000Z*
### [U.S. stock market midday update: Fate Therapeutics rises 23.61%, driven by dual benefits from FDA projects and analyst ratings boosting stock price](https://longbridge.com/en/news/285226003.md)
*2026-05-05T14:38:05.000Z*
> Fate Therap rose 23.61%; Cell Dynamics rose 20.39%, with a transaction volume of USD 683 million; Futu Pharma fell 1.80%

### [Pre-market hot trades in US stocks: Fate Therap up 7.78% in pre-market; Maison Solutions down 7.53% in pre-market](https://longbridge.com/en/news/285196815.md)
*2026-05-05T11:27:27.000Z*
> Fate Therap pre-market up 7.78%; Maison Solutions pre-market down 7.53%; Cellectar Biosciences pre-market up 102.12%; Sa

### [U.S. stock night market fluctuations: Fate Therapeutics rose 7.22% in after-hours trading, analysts raised the target price and the CAR T therapy presentation boosted market confidence](https://longbridge.com/en/news/285141782.md)
*2026-05-05T01:41:15.000Z*
> Fate Therap rose 7.22% in the night session; BeiGene fell 1.99% in the night session, with a transaction volume of USD 9